Axsome Therapeutics, Inc. has entered into a significant $570 million term loan and revolving credit facility with Blackstone Inc., specifically with funds managed by Blackstone Life Sciences and Blackstone Credit & Insurance. This new financial arrangement includes a $500 million term loan facility and a $70 million revolving credit facility. The agreement comes with improved financial terms that are expected to substantially reduce Axsome's interest expenses. Concurrently, Axsome has retired its previous term loan with Hercules Capital by drawing down $120 million from the new term loan facility. The facility bears interest at a SOFR variable rate plus 4.75% for the term loan and SOFR variable rate plus 4.0% for the revolving credit facility, maturing in May 2030 with an interest-only payment period of 60 months. Blackstone also purchased $15 million of Axsome common stock at a price of $107.14 per share. This partnership is designed to enhance Axsome's financial agility and support its growth in the treatment of central nervous system disorders.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。